Companies · Pharmaceuticals

Pharma Solutions USA, Inc. DBA LighthouseAI

PENN VALLEY · Pharmaceuticals

Diligence memoA one-page analyst read on Pharma Solutions USA, Inc. DBA LighthouseAI — recommendation, valuation, rhythm, risks.
$7.2M
Total raised · real
2
Rounds
1.2×
Latest step-up
Top 53%
Sector rank · raised
Series A
Latest stage · inferred · Wed Jun 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Pharma Solutions USA, Inc. DBA LighthouseAI looks over-valued against its niche peers and is at-risk on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 1.72× the median modeled value of Series A Pharmaceuticals companies in 2022–2024 (64 peers) — value vs value, same stage and era.
At-risk
  • Last raise 3.1 yr ago; this sector typically re-raises about every 13 months.
  • Past due for a raise versus sector cadence — watch for distress or a bridge.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

Pharma Solutions USA, Inc. DBA LighthouseAI is one of 1613 Pharmaceuticals companies tracked from PENN VALLEY. By capital raised it ranks mid-pack (ahead of 48% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

pharma

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
11
Investors (latest)
2022
Year incorporated
2023-06-07
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$25M$50M$75M$100MPre-Seed · 2021-11-01 Raised $500K (real) Modeled valuation $11M (est)$500K$11MPre-Seed2021Seed · 2023-06-07 Raised $2.0M (real) Modeled valuation $17M (est)$2.0M$17MSeed2023Series A · 2023-06-07 Raised $5.6M (real) Modeled valuation $47M (est)$5.6M$47MSeries A2023Series A · 2023-06-07 Raised $6.7M (real) Modeled valuation $56M (est)$6.7M$56MSeries A2023+$2.0M+$5.6M+$6.7MCumulative $15M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$500K · 2021
Seed$2.0M · 2023
Series A$5.6M · 2023
Series A extension$6.7M · 2023

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$56.2M
Base estimate est.
$7.7M
Conservative case
$155.4M
Upside case
$30.7M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $10.8M · 2021-11-012021Seed · modeled $16.6M · 2023-06-07Series A · modeled $46.6M · 2023-06-07Series A · modeled $56.2M · 2023-06-072023
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
46%
Survival probability
25% low · 63% high
1.57×/yr
Annual markup
1.97×/yr upside case
3.1 yr
Elapsed time used
3.1 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
6 mo
Avg between rounds
$4.5M/yr
Capital velocity
4.7 yr
On record since
2021
First round
4
Rounds on file
How it compares to the market

Benchmarked against 1613 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.9× of median
This company$7.2M
Sector median$8.1M
Latest round — vs other Series A rounds in sector (real $, this stage) 1.3× above median
This company$6.7M
Sector median$5.2M
Modeled value — vs sector median (estimate, all stages) 0.7× of median
This company$56.2M
Sector median$76.1M

Raised more than 48% of sector peers (real $). Modeled value above 45% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #21 of 64.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)Hallux, Inc. · Series A Raised $20.0M · modeled $151.6M (est)Enalare Therapeutics Inc. · Series A Raised $23.5M · modeled $150.9M (est)Silver Creek Pharmaceuticals, Inc. · Series A Raised $12.6M · modeled $139.3M (est)NQ PE Project Stingray Parent, L.P. · Series A Raised $11.4M · modeled $131.7M (est)Acta Pharmaceuticals, Inc. · Series A Raised $13.4M · modeled $121.5M (est)Groff North America, LLC · Series A Raised $13.1M · modeled $105.9M (est)Hoth Therapeutics, Inc. · Series A Raised $33.7M · modeled $100.6M (est)Eyegate Pharmaceuticals Inc · Series A Raised $72.9M · modeled $92.6M (est)resistanceBio, Inc. · Series A Raised $12.8M · modeled $79.5M (est)T3D Therapeutics, Inc. · Series A Raised $30.0M · modeled $70.9M (est)Aspire BioPharma, Inc. · Series A Raised $10.0M · modeled $69.4M (est)Octagon Therapeutics, Inc. · Series A Raised $12.4M · modeled $68.3M (est)Pharma Solutions USA, Inc. DBA LighthouseAI (this company) Raised $7.2M · modeled $56.2M (est)Pharma Solutions USA, Inc. DBA LighthouseAI
CompanyStageRaised · realValue · estvs peer med.
Hallux, Inc.Series A$20.0M$151.6M4.65×
Enalare Therapeutics Inc.Series A$23.5M$150.9M4.62×
Silver Creek Pharmaceuticals, Inc.Series A$12.6M$139.3M4.27×
NQ PE Project Stingray Parent, L.P.Series A$11.4M$131.7M4.04×
Acta Pharmaceuticals, Inc.Series A$13.4M$121.5M3.72×
Groff North America, LLCSeries A$13.1M$105.9M3.25×
Hoth Therapeutics, Inc.Series A$33.7M$100.6M3.08×
Eyegate Pharmaceuticals IncSeries A$72.9M$92.6M2.84×
resistanceBio, Inc.Series A$12.8M$79.5M2.44×
T3D Therapeutics, Inc.Series A$30.0M$70.9M2.17×
Aspire BioPharma, Inc.Series A$10.0M$69.4M2.13×
Octagon Therapeutics, Inc.Series A$12.4M$68.3M2.09×
Pharma Solutions USA, Inc. DBA LighthouseAI this companySeries A$7.2M$56.2M1.72×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$500K2021-11-01$2.8M$10.8M90%
Seed$2.0M2023-06-07$10.0M$16.6M90%
Series A$5.6M2023-06-07$25.5M$46.6M90%
Series A$6.7M2023-06-07$30.7M$56.2M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$500K2021-11-01
    • First recorded raise — entered as Pre-Seed.
    • 1 investor on this round.
  2. Seed$2.0M2023-06-07
    • Raised 19 mo later, in step with the ~13 mo sector norm.
    • Round 4.0× larger than the prior — scaling up.
    • 2 investors on this round.
  3. Series A$5.6M2023-06-07
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.8× larger than the prior — scaling up.
    • 9 investors on this round.
  4. Series A$6.7M2023-06-07
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 11 investors on this round.
Intelligence
2023 ~Q4
Modeled next raise · ~6mo cadence
$8.1M
Modeled next size est.range $6.7M$13.0M
1.2×
Last step-up
$4.5M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Sunil Shah2 other2023-06
Sandeep Sardana1 other2023-06
Enmi Kendall2023-06
Sumeet Singh2021-11
Registry & provenance

Pharma Solutions USA, Inc. DBA LighthouseAI is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1887135
SEC CIK
2022
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
KinDex Pharmaceuticals, Inc.PharmaceuticalsSeries A$7.5M$27.9Msame sector · same stage
Kirax CorpPharmaceuticalsSeries A$7.0M$25.6Msame sector · same stage
NBO Pharma Inc.PharmaceuticalsSeries A$7.6M$25.7Msame sector · same stage
Kereos, IncPharmaceuticalsSeries A$7.7M$34.9Msame sector · same stage
NuSirt Sciences Inc.PharmaceuticalsSeries A$8.1M$61.9Msame sector · same stage
Sentonix, Inc.PharmaceuticalsSeries A$6.5M$30.2Msame sector · same stage
Companion Spine, LLCPharmaceuticalsSeries A$8.5M$59.0Msame sector · same stage
Optikira, LLCPharmaceuticalsSeries A$8.8M$83.6Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
PharmID, Inc.PharmaceuticalsSeries A$154.9M81%
Strategic Pharmaceutical Solutions, IncPharmaSeries A$46.2M80%
ResQ Pharma, Inc.PharmaceuticalsSeed$3.0M79%
Response Pharmaceuticals, Inc.PharmaceuticalsSeries A$20.5M78%
Pharmaceutical Resource Technology, Inc.PharmaceuticalsSeries A$37.5M78%
Chorda Pharma, Inc.PharmaceuticalsPre-Seed$703K78%
Pharmapotheca A, LLCPharmaceuticalsSeed$87.3M78%
Oncoquest Pharma Usa, IncPharmaceuticalsPre-Seed$10.5M77%
Frequently asked
How much funding has Pharma Solutions USA, Inc. DBA LighthouseAI raised?
Pharma Solutions USA, Inc. DBA LighthouseAI has raised approximately $7.2M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Pharma Solutions USA, Inc. DBA LighthouseAI's estimated valuation?
Provath's modeled valuation for Pharma Solutions USA, Inc. DBA LighthouseAI is approximately $56.2M (modeled range $7.7M–$155.4M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Pharma Solutions USA, Inc. DBA LighthouseAI at?
Pharma Solutions USA, Inc. DBA LighthouseAI's latest modeled financing stage is Series A. Its most recent recorded round closed around Wed Jun 07.
What does Pharma Solutions USA, Inc. DBA LighthouseAI do and where is it based?
Pharma Solutions USA, Inc. DBA LighthouseAI operates in the Pharmaceuticals sector, based in PENN VALLEY.
Explore related

See where Pharma Solutions USA, Inc. DBA LighthouseAI sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Pharma Solutions USA, Inc. DBA LighthouseAI, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.